Unicycive Therapeutics, Inc. (UNCY)Healthcare | Biotechnology | Mountain View, United States | NasdaqCM
5.09 USD
-0.12
(-2.303%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.06 -0.03 (-0.030%) ⇩ (July 13, 2026, 7:45 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:37 a.m. EDT
The investment case for Unicycive Therapeutics is currently broken by a catastrophic multi-year decline and a specific regulatory failure. Despite a recent technical bounce and a modest year-over-year gain, the stock has lost nearly 90% of its value over the last four years, with the most recent annual period showing a severe -60% drop. This is not a temporary correction; it is a structural implosion driven by the FDA's issuance of a Complete Response Letter regarding manufacturing issues for their kidney disease drug. The market has correctly priced this as a potential value trap where the business model is under existential threat. While analysts project a massive upside based on theoretical potential, the reality of the rejected application and the company's burning cash pile makes holding this position dangerous. The options market confirms this pessimism, with traders buying deep out-of-the-money puts to hedge against further ruin rather than betting on a comeback. Until the FDA issues a new approval or a credible path to resolution is demonstrated, the long-term outlook remains bleak. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.082458 |
| AutoTheta | 0.084170 |
| AutoETS | 0.085185 |
| AutoARIMA | 0.085186 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 2.19 |
| Ljung-Box p | 0.001 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 5.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.162 |
| Market Cap | 139,430,512 |
| Forward P/E | 0.99 |
| Beta | 1.79 |
| Website | https://unicycive.com |
As of July 11, 2026, 4:37 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes at 2.5) compared to negligible call volume. This indicates a strong consensus fear of further price collapse rather than a bullish bet on recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.0676229 |
| Address1 | 1,975 West El Camino Real |
| Address2 | Suite 204 |
| All Time High | 87.3 |
| All Time Low | 2.02 |
| Ask | 6.37 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 4,720,400 |
| Average Daily Volume3 Month | 1,437,209 |
| Average Volume | 1,437,209 |
| Average Volume10Days | 4,720,400 |
| Beta | 1.787 |
| Bid | 3.68 |
| Bid Size | 2 |
| Book Value | 1.494 |
| City | Mountain View |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.09 |
| Current Ratio | 2.399 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.19 |
| Day Low | 4.94 |
| Debt To Equity | 2.162 |
| Display Name | Unicycive Therapeutics |
| Earnings Timestamp End | 1,747,221,300 |
| Earnings Timestamp Start | 1,747,221,300 |
| Ebitda | -29,931,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.744 |
| Enterprise Value | 82,132,136 |
| Eps Current Year | -1.415 |
| Eps Forward | 5.14625 |
| Eps Trailing Twelve Months | -2.19 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.2426 |
| Fifty Day Average Change | -2.1525998 |
| Fifty Day Average Change Percent | -0.29721367 |
| Fifty Two Week Change Percent | 6.76229 |
| Fifty Two Week High | 8.74 |
| Fifty Two Week High Change | -3.6499996 |
| Fifty Two Week High Change Percent | -0.4176201 |
| Fifty Two Week Low | 3.71 |
| Fifty Two Week Low Change | 1.3800001 |
| Fifty Two Week Low Change Percent | 0.37196767 |
| Fifty Two Week Range | 3.71 - 8.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,096,600,000 |
| Float Shares | 24,280,471 |
| Forward Eps | 5.14625 |
| Forward P E | 0.98906976 |
| Free Cashflow | -6,922,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02358 |
| Held Percent Institutions | 0.32652 |
| Implied Shares Outstanding | 27,393,027 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-13 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,750,377,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California. |
| Long Name | Unicycive Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 139,430,512 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_605176729 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -39,888,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 143,128,566 |
| Number Of Analyst Opinions | 10 |
| Open | 5.19 |
| Operating Cashflow | -28,655,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 351 4495 |
| Post Market Change | -0.030100346 |
| Post Market Change Percent | -0.59136236 |
| Post Market Price | 5.0599 |
| Post Market Time | 1,783,986,301 |
| Previous Close | 5.21 |
| Price Eps Current Year | -3.5971735 |
| Price Hint | 2 |
| Price To Book | 3.4069614 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.061 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -0.12 |
| Regular Market Change Percent | -2.30326 |
| Regular Market Day High | 5.19 |
| Regular Market Day Low | 4.94 |
| Regular Market Day Range | 4.94 - 5.19 |
| Regular Market Open | 5.19 |
| Regular Market Previous Close | 5.21 |
| Regular Market Price | 5.09 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,125,901 |
| Return On Assets | -0.40557998 |
| Return On Equity | -1.63136 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 27,393,027 |
| Shares Percent Shares Out | 0.1705 |
| Shares Short | 4,671,324 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,837,490 |
| Short Name | Unicycive Therapeutics, Inc. |
| Short Percent Of Float | 0.1745 |
| Short Ratio | 1.94 |
| Source Interval | 15 |
| State | CA |
| Symbol | UNCY |
| Target High Price | 90.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 38.59 |
| Target Median Price | 33.5 |
| Total Cash | 54,586,000 |
| Total Cash Per Share | 2.044 |
| Total Debt | 815,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.302825 |
| Two Hundred Day Average Change | -1.2128248 |
| Two Hundred Day Average Change Percent | -0.1924256 |
| Type Disp | Equity |
| Volume | 1,125,901 |
| Website | https://unicycive.com |
| Zip | 94,040 |